iCell Gene Therapeutics is proud to announce the publication of a proof-of-concept article for NK cells. In our article, "Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies", we demonstrate the preclinical efficacy of NK cells directed to the CD3 antigen as a novel approach for targeting T-cell malignancies. Read about it more here


Comments are closed.